In depth
Polymyalgia rheumatica and blood tests
No blood test diagnoses polymyalgia rheumatica, and the markers support a clinical diagnosis rather than being in for one. This site holds no diagnostic accuracy study for either marker in this condition. So every accuracy figure below here is borrowed from a study done in some other disease altogether.
What the research found.
The usual age rule for the sedimentation rate comes in two forms. For men, take your age and halve it, and for women, add ten to your age first, then halve it. Applying that rule removed an apparent age difference entirely, in one group of 263 patients with the disease.
Twenty-three of the 130 giant cell arteritis patients in one series had a normal sedimentation rate and a normal CRP. For that diagnosis, CRP caught 74 percent of the cases. The sedimentation rate caught 48 percent, so a test that misses more than half is being asked to reassure.
Starting vitamin D didn't differ between patients and controls, coming in at 21.6 against 22.7 nanograms per milliliter. The three-month change predicted early remission at an odds ratio of 2.89. The true value ranges from 1.60 to 4.11, which is a wide interval and doesn't touch 1 anywhere.
One study covered 198 patients with polymyalgia rheumatica, giant cell arteritis, or another vasculitis. Two dose measures were associated with nothing, which are the current glucocorticoid dose and the total taken over time. Three other things did, which are a lower body mass index, a past spine fracture, and taking a heartburn drug.
What the number means.
| Test | What it measures | What it does in this condition | What it can't do |
|---|---|---|---|
| ESR | How fast red cells settle, affected by inflammation, age, anemia, and pregnancy | Supports a clinical diagnosis and tends to be raised at presentation | Diagnose this condition. We hold no accuracy study for it in polymyalgia rheumatica |
| ESR, age-adjusted | The conventional upper limit rises with age | Does more work here than elsewhere, because this disease starts after 50 | Be applied without knowing the person's age and sex |
| CRP | A protein the liver makes in response to inflammation, moving within a day or two | Used the same way as ESR and moves faster than it does | Diagnose this condition either, and no accuracy figure for it here is from a polymyalgia cohort |
| Both together, for giant cell arteritis | The overlapping disease that threatens sight | 23 of 130 patients with that disease had a normal pair | Exclude giant cell arteritis. That's the safety point on this page |
| Vitamin D, as 25(OH)D | Stored vitamin D in the blood | Baseline didn't differ from controls, at 21.6 against 22.7 nanograms per milliliter | Be used as a disease marker. Its correlation with CRP and ESR wasn't significant |
| Bone density T-score | Not a marker of disease, and relevant on long-term corticosteroids | Wasn't associated with corticosteroid dose in 198 patients on these treatments | Be predicted from your corticosteroid dose alone |
A reference range is not a target. Where a range on this page differs from the one your laboratory prints, the difference is explained above and sourced below. Where no trial has tested a target, this page says so rather than offering one.
There's no blood test for this diagnosis
Polymyalgia rheumatica is diagnosed clinically, which means from the symptoms, the examination, and the response to treatment. The sedimentation rate and CRP support that judgment rather than making it. Neither result confirms the diagnosis, and neither result excludes it either, which is the whole of the position.
This site holds no diagnostic accuracy study for either test in polymyalgia rheumatica, which is a real hole on a page about blood tests. It's worth saying before any figure appears anywhere below it. Every accuracy number here is borrowed from a study in a different condition, and the page says so each time.
You may want the one number that settles this, and that number doesn't exist yet. The useful work on this page is somewhere else entirely. It's in how to read a marker you already have, and in the one situation where a normal result is dangerous.
Why your age changes your sedimentation rate
The sedimentation rate measures how fast red cells settle in a tube, and swelling affects that, as do your age, low blood counts, and pregnancy. The age effect is large, so the usual upper limit of normal isn't a fixed figure. It's a formula, where men take their age and halve it, and women add ten first, then halve it.
That correction does more work here than almost anywhere else, because this disease begins after 50. The series we hold had a mean age of 73.4 years. Take a 78-year-old woman, whose upper limit is 44, so a result of 40 is normal for her. Her lab report may still flag it, because that printed range was built for a younger population.
The rule comes from population figures rather than from an outcome study, and that's how it should be read. One cohort had 263 patients, and applying the rule removed an apparent age difference entirely. That was the difference between older and younger onset, so the rule looks sound, though it isn't proof of anything more than that. Acting on the adjusted number may change nothing for anybody.
The overlap that makes a normal marker risky
Polymyalgia rheumatica and giant cell arteritis share a clinic, and often a patient. Giant cell arteritis can take your sight suddenly and for good, so this is the one place on the page where a normal test misleads. Don't lean on a normal result here, and the numbers below explain why.
One fast-track clinic series had 130 patients with giant cell arteritis, and 23 of them had a normal sedimentation rate and a normal CRP. For that diagnosis CRP caught 74 percent of cases and ESR caught 48 percent. So a test that misses more than half is being asked to reassure. Those figures come from a group already suspected of the disease, which lifts the catch rate rather than lowering it.
So the practical rule doesn't depend on your markers at all. Four things need urgent assessment on the day, which are a new headache, jaw pain that comes on with chewing, a tender scalp, and any change in vision. Your last blood tests aren't the question, and normal ones shouldn't decide it.
What the vitamin D finding does and doesn't say
Vitamin D comes up here for two separate reasons. The first is bone protection on long-term corticosteroids, which the diet page covers rather than this one. The second is a study that looked back at records and found something much less settled.
Starting vitamin D didn't differ between patients and controls, at 21.6 against 22.7 nanograms per milliliter. The three-month change was much larger in those reaching remission and smaller in those whose disease stayed active. Once other factors were allowed for, that change still predicted remission at an odds ratio of 2.89, with the true value from 1.60 to 4.11. Prednisone dose and cumulative glucocorticoid exposure weren't significant predictors in that model.
That study was retrospective, observational, and small, so it can't establish direction. People who respond well to treatment may differ in other ways, absorbing it better, storing it better, or being given it more often. The study can't separate those from an effect of the vitamin itself. A separate and much smaller series looked for a link with the markers and found no link with CRP, at a P value of 0.613, and no link with ESR, at 0.696. So this isn't a test that tracks your disease activity.
The measurement worth having that isn't a disease marker
Bone density isn't a marker of polymyalgia rheumatica, and it's still the test most worth having on long corticosteroid treatment. Most people with this diagnosis are on it. The relationship with dose is less direct than most people expect, and reading it carefully changes what you ask for.
One study covered 198 patients with polymyalgia rheumatica, giant cell arteritis, or another vasculitis, and neither dose measure was associated with the lowest T-score. Not the current glucocorticoid dose, and not the total over time. Three other things were associated with lower bone density, which are a lower body mass index, a past spine fracture, and taking a proton-pump inhibitor, which is a heartburn drug. That study looked at people at one moment, most already on bone protection, so it can't show what a trial would.
So the case is for bone protection rather than for predicting your own risk from your dose. Take a woman on a modest dose who has a low body mass index and takes a heartburn drug. She isn't obviously safer than somebody on more corticosteroid without those, and mentioning all three at the appointment is more useful than reciting your milligrams.
What the sources here don't cover
Nothing here says how often your markers should be rechecked, and the reason is specific. Our record for the 2015 international recommendations says the full text returned an error every time, so the guideline wording was never read. This page won't describe a recheck schedule from memory, and it leaves the question with your team.
Two other subjects a reader will meet are absent for a similar reason. This site holds no source on ultrasound of the shoulders and hips, and that scan gets used in assessment. We hold nothing on the 2012 classification rules that many clinicians work from either. Both would belong on a complete page about testing in this condition.
Those absences are recorded in the review notes rather than filled with estimates. A figure that sounds right is worse than an admitted hole, and that holds for a test this important. A plausible number gets quoted onward, and supplying the references is what would let this page cover the subject properly.
Common misconceptions.
Myth. A blood test will confirm whether I have polymyalgia rheumatica.
Reality. It won't, because the diagnosis is clinical and the markers support it rather than settling it. This site holds no accuracy study for ESR or CRP in this disease at all, which is a real absence on a page about blood tests. The figures quoted here for those two tests come from giant cell arteritis groups and a rheumatoid arthritis group, so both are borrowed rather than about this disease.
Myth. My sedimentation rate of 40 is high.
Reality. That depends on your age and sex, and the correction does real work in this condition. The usual upper limit has two forms, which are your age halved for men, and ten added to your age before halving for women. So a 78-year-old woman is 44 before anything counts as abnormal. One cohort had 263 patients, and applying that adjustment removed an apparent age difference entirely.
Myth. Normal markers mean I don't need to worry about giant cell arteritis.
Reality. One fast-track clinic series had 130 patients with giant cell arteritis, and 23 of them had a normal sedimentation rate and a normal CRP. CRP caught 74 percent of the cases and ESR caught only 48 percent, so both tests miss people. That disease can take your sight suddenly and for good, so a new headache, jaw pain when you chew, and any change in your vision all need urgent assessment, whatever the blood tests said.
Myth. My vitamin D level tells me how active my disease is.
Reality. Starting levels in the better study didn't differ from controls, at 21.6 against 22.7 nanograms per milliliter. In a much smaller series, vitamin D showed no real link with CRP at a P value of 0.613, and no link with ESR at 0.696. One study looked back at records and found the three-month change predicted early remission, at an odds ratio of 2.89. That's a link found inside a treated group rather than a disease marker.
Cautions specific to this condition.
- Ask for your age-adjusted upper limit, because the lab's flag isn't it. The printed range for ESR usually ignores your age and sex.
- Four things need urgent care whatever your last markers showed: a new headache, jaw pain when you chew, a tender scalp, and any change in your vision. In one series, 23 of 130 giant cell arteritis patients had a normal pair.
- Mention a heartburn drug if you take one. It was one of three things associated with lower bone density. That was in the study of 198 patients on these treatments.
- Ask what your markers are being followed for. This site holds no source on how well they do that job. Nothing covers ESR or CRP for monitoring rather than for supporting the diagnosis.
Discuss any change with the rheumatologist who manages your care. Nothing here replaces that conversation.
Questions patients ask.
Is there a blood test for polymyalgia rheumatica?
There isn't one, and that's the most useful thing to know before an appointment. The diagnosis is made clinically, and the sedimentation rate and CRP support that judgment without confirming it or ruling it out. This site holds no study of how well either test does here. So one number is missing, which is how often the tests read normal in people who have the disease.
How should I read my sedimentation rate?
Against your age and sex rather than against the printed range. The usual age rule has two forms, which are your age halved for men, and ten added first for women. So the limit rises as people get older, and applying that rule removed an apparent age difference entirely in one group of 263 patients. Don't read a slightly raised result in an older person as automatically meaningful.
What numbers are typical at diagnosis?
This site holds no figure good enough to answer that question. What we had came from 8 patients, which is far too few to describe what's typical, so it came off the page. Ask your own team what your own numbers were and what they make of them. A made-up typical range would be worse than no range at all, because a plausible number gets quoted onward.
Can I have giant cell arteritis with normal blood tests?
You can, and it's the one safety fact to hold on to here. One series had 130 patients with giant cell arteritis, and 23 of them had a normal sedimentation rate and a normal CRP. CRP caught 74 percent of the cases and ESR caught 48 percent, so a normal pair doesn't rule the disease out. A new headache, jaw pain when you chew, or a change in vision needs urgent care.
Should my vitamin D be checked?
It's reasonable on long-term corticosteroid treatment, though it isn't a way to follow your disease. Starting levels didn't differ from controls, at 21.6 against 22.7 nanograms per milliliter, and a smaller series found no real link with CRP or ESR. One study looked back at records and found the three-month change predicted early remission, at an odds ratio of 2.89. That's worth discussing before anybody acts on it.
How often should my markers be rechecked?
Nothing in our sources answers that, and the reason is worth stating plainly. Our record for the 2015 international recommendations says the full text couldn't be retrieved, so we hold no guideline wording on monitoring intervals here. Ask your team what interval they're working to, and what a change would prompt. That's a better use of the question than any figure on this page would be.
What about my bones on long-term steroids?
Bone density isn't a marker of polymyalgia rheumatica, and it's still the test most worth having on long corticosteroid treatment. One study covered 198 patients with these diagnoses, where neither the current corticosteroid dose nor the total taken over time was associated with anything. A lower body mass index, a past spine fracture, and a heartburn drug all did. So the case is for bone protection rather than for predicting your risk from your dose.
References.
- Ranganath VK; Elashoff DA; Khanna D et al. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. The Journal of rheumatology. 2005;32:1040-2. PMID 15940764Observational cohort analysis of 263 patients with early seropositive RA enrolled within 14 months of symptom onset
- Currier C; Bays A; Thomason J. Normal inflammatory markers in giant cell arteritis: a diagnostic blind spot. Rheumatology International. 2025;45. 10.1007/s00296-025-05930-3Retrospective diagnostic accuracy study within a single fast-track GCA clinic
- Hysa E; Balito S; Davoli G et al. Vitamin D Status and Response to Supplementation as Predictive Factors for Early Remission in Polymyalgia Rheumatica: A Retrospective Longitudinal Investigation. Nutrients. 2025;17:2839. 10.3390/nu17172839Retrospective observational case-control study with a longitudinal subgroup
- Palmowski A; Wiebe E; Muche B et al. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort. Cells. 2022;11:536. 10.3390/cells11030536Cross-sectional baseline analysis of a prospective cohort
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.
Across the site